Healthcare - Biotechnology - NASDAQ - US
$ 0.043
3.61 %
$ 2.34 M
Market Cap
-0.09
P/E
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer and locally advanced pancreatic cancer.[ Read More ]
The intrinsic value of one GRTX stock under the base case scenario is HIDDEN Compared to the current market price of 0.043 USD, Galera Therapeutics, Inc. is HIDDEN
2. FUNDAMENTAL
ANALYSIS
Price Chart GRTX
FINANCIALS
0
REVENUE
-47 M
OPERATING INCOME
-59.1 M
NET INCOME
-44.8 M
OPERATING CASH FLOW
27.3 M
INVESTING CASH FLOW
31.5 M
FINANCING CASH FLOW
0
REVENUE
-4.21 M
OPERATING INCOME
-4.06 M
NET INCOME
-2.72 M
OPERATING CASH FLOW
0
INVESTING CASH FLOW
0
FINANCING CASH FLOW
Balance Sheet Decomposition
Galera Therapeutics, Inc.
| Current Assets | 21.6 M |
| Cash & Short-Term Investments | 18.3 M |
| Receivables | 0 |
| Other Current Assets | 3.37 M |
| Non-Current Assets | 4.51 M |
| Long-Term Investments | 0 |
| PP&E | 1.28 M |
| Other Non-Current Assets | 3.23 M |
| Current Liabilities | 4.96 M |
| Accounts Payable | 1.38 M |
| Short-Term Debt | 266 K |
| Other Current Liabilities | 3.32 M |
| Non-Current Liabilities | 152 M |
| Long-Term Debt | 1.12 M |
| Other Non-Current Liabilities | 151 M |
EFFICIENCY
Earnings Waterfall
Galera Therapeutics, Inc.
| Revenue | 0 |
| Cost Of Revenue | 259 K |
| Gross Profit | -259 K |
| Operating Expenses | 47 M |
| Operating Income | -47 M |
| Other Expenses | 12.1 M |
| Net Income | -59.1 M |
RATIOS
0.00%
GROSS MARGIN
0.00%
OPERATING MARGIN
0.00%
NET MARGIN
45.04%
ROE
-226.01%
ROA
35.83%
ROIC
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Galera Therapeutics, Inc.
| Net Income | -59.1 M |
| Depreciation & Amortization | 259 K |
| Capital Expenditures | -59 K |
| Stock-Based Compensation | 5.56 M |
| Change in Working Capital | -2.93 M |
| Others | 10.6 M |
| Free Cash Flow | -44.9 M |
Wall Street Analysts Price Targets
Galera Therapeutics, Inc.
GRTX has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00%
DIVIDEND YIELD
0 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Galera Therapeutics, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
4.83 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
530 K USD 1
6-9 MONTHS
166 K USD 1
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
3 months ago
Aug 16, 2024
|
Sell 4.83 K USD
|
Sorensen Mel
President and CEO |
- 67015
|
0.072 USD |
|
6 months ago
Apr 19, 2024
|
Bought 19.3 K USD
|
Schneid Yair
10 percent owner |
+ 99371
|
0.194 USD |
|
6 months ago
Apr 19, 2024
|
Bought 40.3 USD
|
Schneid Yair
10 percent owner |
+ 215
|
0.1875 USD |
|
6 months ago
Apr 19, 2024
|
Bought 58.8 USD
|
Schneid Yair
10 percent owner |
+ 314
|
0.1874 USD |
|
6 months ago
Apr 19, 2024
|
Bought 18.6 USD
|
Schneid Yair
10 percent owner |
+ 100
|
0.1855 USD |
|
7 months ago
Apr 18, 2024
|
Bought 14.8 K USD
|
Schneid Yair
10 percent owner |
+ 74202
|
0.2 USD |
|
7 months ago
Apr 18, 2024
|
Bought 868 USD
|
Schneid Yair
10 percent owner |
+ 4342
|
0.1999 USD |
|
7 months ago
Apr 18, 2024
|
Bought 848 USD
|
Schneid Yair
10 percent owner |
+ 4245
|
0.1998 USD |
|
7 months ago
Apr 18, 2024
|
Bought 49 K USD
|
Schneid Yair
10 percent owner |
+ 247600
|
0.198 USD |
|
7 months ago
Apr 18, 2024
|
Bought 19.7 K USD
|
Schneid Yair
10 percent owner |
+ 100000
|
0.197 USD |
|
7 months ago
Apr 18, 2024
|
Bought 18.9 K USD
|
Schneid Yair
10 percent owner |
+ 100000
|
0.1893 USD |
|
7 months ago
Apr 18, 2024
|
Bought 3.18 K USD
|
Schneid Yair
10 percent owner |
+ 17211
|
0.185 USD |
|
7 months ago
Apr 17, 2024
|
Bought 109 K USD
|
Schneid Yair
10 percent owner |
+ 453988
|
0.24 USD |
|
7 months ago
Apr 17, 2024
|
Bought 127 K USD
|
Schneid Yair
10 percent owner |
+ 551217
|
0.23 USD |
|
7 months ago
Apr 17, 2024
|
Bought 53.5 K USD
|
Schneid Yair
10 percent owner |
+ 243100
|
0.22 USD |
|
7 months ago
Apr 17, 2024
|
Bought 10.7 K USD
|
Schneid Yair
10 percent owner |
+ 50000
|
0.214 USD |
|
7 months ago
Apr 17, 2024
|
Bought 10.6 K USD
|
Schneid Yair
10 percent owner |
+ 50000
|
0.212 USD |
|
7 months ago
Apr 17, 2024
|
Bought 11.9 K USD
|
Schneid Yair
10 percent owner |
+ 56900
|
0.21 USD |
|
7 months ago
Apr 17, 2024
|
Bought 48.2 K USD
|
Schneid Yair
10 percent owner |
+ 241028
|
0.2 USD |
|
7 months ago
Apr 17, 2024
|
Bought 13.4 K USD
|
Schneid Yair
10 percent owner |
+ 68424
|
0.196 USD |
|
7 months ago
Apr 17, 2024
|
Bought 19.1 K USD
|
Schneid Yair
10 percent owner |
+ 100000
|
0.191 USD |
|
10 years ago
Apr 17, 2014
|
Bought 60.4 K USD
|
Schneid Yair
10 percent owner |
+ 318150
|
0.19 USD |
|
9 months ago
Feb 08, 2024
|
Bought 25.7 K USD
|
Schneid Yair
10 percent owner |
+ 150000
|
0.171 USD |
|
9 months ago
Feb 07, 2024
|
Bought 25.9 K USD
|
Schneid Yair
10 percent owner |
+ 150000
|
0.1729 USD |
|
9 months ago
Feb 07, 2024
|
Bought 4.25 K USD
|
Schneid Yair
10 percent owner |
+ 25000
|
0.17 USD |
|
9 months ago
Feb 06, 2024
|
Bought 5.02 K USD
|
Schneid Yair
10 percent owner |
+ 25000
|
0.201 USD |
|
9 months ago
Feb 05, 2024
|
Bought 17.9 K USD
|
Schneid Yair
10 percent owner |
+ 97402
|
0.184 USD |
|
9 months ago
Jan 30, 2024
|
Bought 60.6 K USD
|
Schneid Yair
10 percent owner |
+ 335000
|
0.181 USD |
|
9 months ago
Jan 29, 2024
|
Bought 27 K USD
|
Schneid Yair
10 percent owner |
+ 150000
|
0.18 USD |
|
1 year ago
Mar 16, 2023
|
Bought 24.7 K USD
|
Bachleda Mark
Chief Commercial Officer |
+ 11000
|
2.247 USD |
|
1 year ago
Mar 10, 2023
|
Bought 168 K USD
|
Sorensen Mel
President and CEO |
+ 100000
|
1.6812 USD |
|
1 year ago
Mar 13, 2023
|
Bought 19.6 K USD
|
Degnan Chris
Chief Financial Officer |
+ 10000
|
1.9593 USD |
|
2 years ago
Dec 17, 2021
|
Bought 54.8 K USD
|
West Linda
Director |
+ 20000
|
2.7402 USD |
|
3 years ago
Sep 01, 2021
|
Sell 404 K USD
|
HOLMLUND JON T
Chief Medical Officer |
- 47756
|
8.4701 USD |
|
3 years ago
Jun 15, 2021
|
Bought 91.3 K USD
|
West Linda
Director |
+ 10000
|
9.13 USD |
|
3 years ago
Jun 02, 2021
|
Bought 86.5 K USD
|
West Linda
Director |
+ 10000
|
8.6511 USD |
|
3 years ago
Jun 01, 2021
|
Bought 34.7 K USD
|
Alleva Lawrence M
Director |
+ 4045
|
8.5887 USD |
|
3 years ago
Jun 01, 2021
|
Bought 86.4 K USD
|
West Linda
Director |
+ 10000
|
8.6381 USD |
|
3 years ago
May 28, 2021
|
Bought 86.4 K USD
|
West Linda
Director |
+ 10000
|
8.641 USD |
|
3 years ago
Feb 18, 2021
|
Sell 5.29 M USD
|
Novo Holdings A/S
10 percent owner |
- 500000
|
10.58 USD |
|
4 years ago
Nov 13, 2020
|
Bought 23.8 K USD
|
Alleva Lawrence M
Director |
+ 2325
|
10.2242 USD |
|
4 years ago
Nov 13, 2020
|
Sell 103 K USD
|
Sussman Joel F.
Chief Accounting Officer |
- 10000
|
10.3197 USD |
|
4 years ago
Nov 12, 2020
|
Sell 101 K USD
|
Sussman Joel F.
Chief Accounting Officer |
- 10000
|
10.0627 USD |
|
4 years ago
Oct 26, 2020
|
Sell 33.7 K USD
|
HOLMLUND JON T
Chief Medical Officer |
- 2244
|
15 USD |
|
4 years ago
Oct 15, 2020
|
Sell 4.95 M USD
|
Novo Holdings A/S
10 percent owner |
- 450000
|
11 USD |
|
4 years ago
Oct 06, 2020
|
Sell 126 K USD
|
HOLMLUND JON T
Chief Medical Officer |
- 10536
|
12 USD |
|
4 years ago
Jun 18, 2020
|
Sell 8.14 K USD
|
Novartis Bioventures Ltd
|
- 900
|
9.04 USD |
|
4 years ago
Jun 19, 2020
|
Sell 8.26 M USD
|
Novartis Bioventures Ltd
|
- 1001312
|
8.25 USD |
|
4 years ago
Jun 15, 2020
|
Sell 55.8 K USD
|
Novartis Bioventures Ltd
10 percent owner |
- 6164
|
9.05 USD |
|
4 years ago
Jun 16, 2020
|
Sell 80 K USD
|
Novartis Bioventures Ltd
10 percent owner |
- 8600
|
9.3 USD |
|
4 years ago
Jun 17, 2020
|
Sell 42.8 K USD
|
Novartis Bioventures Ltd
10 percent owner |
- 4622
|
9.27 USD |
|
4 years ago
Jun 10, 2020
|
Sell 80.7 K USD
|
Novartis Bioventures Ltd
10 percent owner |
- 8532
|
9.46 USD |
|
4 years ago
Jun 11, 2020
|
Sell 66.3 K USD
|
Novartis Bioventures Ltd
10 percent owner |
- 7200
|
9.21 USD |
|
4 years ago
Jun 12, 2020
|
Sell 13.8 K USD
|
Novartis Bioventures Ltd
10 percent owner |
- 1500
|
9.19 USD |
|
4 years ago
Jun 05, 2020
|
Sell 83.6 K USD
|
Novartis Bioventures Ltd
10 percent owner |
- 8652
|
9.66 USD |
|
4 years ago
Jun 08, 2020
|
Sell 54.7 K USD
|
Novartis Bioventures Ltd
10 percent owner |
- 5659
|
9.66 USD |
|
4 years ago
Jun 09, 2020
|
Sell 65.7 K USD
|
Novartis Bioventures Ltd
10 percent owner |
- 7000
|
9.38 USD |
|
4 years ago
Jun 02, 2020
|
Sell 54.9 K USD
|
Novartis Bioventures Ltd
10 percent owner |
- 5669
|
9.68 USD |
|
4 years ago
Jun 03, 2020
|
Sell 50.9 K USD
|
Novartis Bioventures Ltd
10 percent owner |
- 5208
|
9.78 USD |
|
4 years ago
Jun 04, 2020
|
Sell 39 K USD
|
Novartis Bioventures Ltd
10 percent owner |
- 4088
|
9.55 USD |
|
4 years ago
May 26, 2020
|
Sell 8.3 K USD
|
HOLMLUND JON T
Chief Medical Officer |
- 692
|
12 USD |
|
4 years ago
May 21, 2020
|
Sell 14.1 K USD
|
HOLMLUND JON T
Chief Medical Officer |
- 1174
|
12 USD |
|
4 years ago
May 12, 2020
|
Sell 8.05 K USD
|
HOLMLUND JON T
Chief Medical Officer |
- 671
|
12 USD |
|
4 years ago
May 07, 2020
|
Sell 24.7 K USD
|
HOLMLUND JON T
Chief Medical Officer |
- 2059
|
12.0007 USD |
|
4 years ago
May 06, 2020
|
Sell 17.9 K USD
|
HOLMLUND JON T
Chief Medical Officer |
- 1489
|
12 USD |
|
4 years ago
May 05, 2020
|
Sell 37.3 K USD
|
HOLMLUND JON T
Chief Medical Officer |
- 3064
|
12.16 USD |
|
4 years ago
Dec 13, 2019
|
Bought 39.1 K USD
|
Alleva Lawrence M
Director |
+ 4000
|
9.7847 USD |
|
5 years ago
Nov 12, 2019
|
Bought 1.17 M USD
|
Clarus IV-A, L.P.
10 percent owner |
+ 97131
|
12 USD |
|
5 years ago
Nov 12, 2019
|
Bought 969 K USD
|
Clarus IV-A, L.P.
10 percent owner |
+ 80786
|
12 USD |
|
5 years ago
Nov 12, 2019
|
Bought 632 K USD
|
Clarus IV-A, L.P.
10 percent owner |
+ 52660
|
12 USD |
|
5 years ago
Nov 12, 2019
|
Bought 233 K USD
|
Clarus IV-A, L.P.
10 percent owner |
+ 19423
|
12 USD |
|
5 years ago
Nov 12, 2019
|
Bought 1.17 M USD
|
Blackstone Clarus GP L.P.
10 percent owner |
+ 97131
|
12 USD |
|
5 years ago
Nov 12, 2019
|
Bought 969 K USD
|
Blackstone Clarus GP L.P.
10 percent owner |
+ 80786
|
12 USD |
|
5 years ago
Nov 12, 2019
|
Bought 632 K USD
|
Blackstone Clarus GP L.P.
10 percent owner |
+ 52660
|
12 USD |
|
5 years ago
Nov 12, 2019
|
Bought 233 K USD
|
Blackstone Clarus GP L.P.
10 percent owner |
+ 19423
|
12 USD |
|
5 years ago
Nov 12, 2019
|
Bought 6 M USD
|
Novo Holdings A/S
10 percent owner |
+ 500000
|
12 USD |
|
5 years ago
Nov 12, 2019
|
Bought 5 M USD
|
New Enterprise Associates 14, L.P.
10 percent owner |
+ 416666
|
12 USD |
|
5 years ago
Nov 12, 2019
|
Bought 9 M USD
|
Sofinnova Venture Partners IX, L.P.
10 percent owner |
+ 750000
|
12 USD |
|
5 years ago
Nov 12, 2019
|
Bought 3 M USD
|
Novartis Bioventures Ltd
10 percent owner |
+ 250000
|
12 USD |
7. News
Galera Announces Board Approval of Complete Liquidation and Dissolution
MALVERN, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company historically focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that its Board of Directors has approved a Plan of Liquidation and Dissolution (Plan of Dissolution), which provides for the dissolution of the Company under Delaware law, and plans to seek stockholder approval of the Plan of Dissolution at a special meeting of stockholders to be held on or around October 17, 2024.
globenewswire.com
- 3 months ago
Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates
MALVERN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced financial results for the first quarter ended March 31, 2024, and provided recent corporate updates.
globenewswire.com
- 6 months ago
Galera Adopts Limited Duration Stockholder Rights Agreement
MALVERN, Pa., May 03, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that its Board of Directors (the “Board”) has unanimously resolved to adopt a limited duration stockholder rights agreement (the “Rights Agreement”) to protect stockholder interests.
globenewswire.com
- 6 months ago
Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates
Company continues to evaluate strategic options to maximize shareholder value Company continues to evaluate strategic options to maximize shareholder value
globenewswire.com
- 7 months ago
Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
FDA confirms need for new trial for avasopasem; GRECO trials with rucosopasem to be discontinued Company evaluating potential strategic options to optimize shareholder value MALVERN, Pa., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced financial results for the third quarter ended September 30, 2023 and provided recent corporate updates.
globenewswire.com
- 1 year ago
Galera Announces Receipt of Type A Meeting Minutes and Strategic Update
FDA confirms need for new trial for avasopasem for severe oral mucositis (SOM) GRECO-2 trial did not pass futility analysis; Company will discontinue both GRECO trials Company reviewing potential strategic alternatives to maximize shareholder value MALVERN, Pa., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that it has received official meeting minutes from the Type A meeting with the United States Food and Drug Administration (FDA) held September 28, 2023 in which the FDA reiterated the need for an additional Phase 3 trial of avasopasem manganese (avasopasem) for radiotherapy-induced SOM.
globenewswire.com
- 1 year ago
Galera Schedules Type A Meeting with FDA to Discuss Next Steps for Avasopasem
MALVERN, Pa., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that a Type A Meeting has been scheduled for September 28, 2023 with the U.S. Food and Drug Administration (FDA) regarding the Complete Response Letter (CRL) received for the Company's New Drug Application (NDA) for avasopasem manganese (avasopasem). The FDA is expected to issue written meeting minutes approximately 30 days following the meeting.
globenewswire.com
- 1 year ago
Top 5 Health Care Stocks That May Explode In Q3 - BioVie (NASDAQ:BIVI), Galera Therapeutics (NASDAQ:GRTX)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
benzinga.com
- 1 year ago
All You Need to Know About Galera Therapeutics, Inc. (GRTX) Rating Upgrade to Buy
Galera Therapeutics, Inc. (GRTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
zacks.com
- 1 year ago
3 Biotech Stocks Poised to Beat Q2 Earnings Estimates
We look at a few biotech companies, LEGN, KOD, GRTX, which are poised to beat second-quarter earnings estimates.
zacks.com
- 1 year ago
Galera Reports Second Quarter 2023 Financial Results and Recent Corporate Updates
Company received Complete Response Letter from FDA for avasopasem and intends to request Type A meeting with FDA to discuss potential next steps
globenewswire.com
- 1 year ago
Galera Therapeutics shares plummet after FDA rejects drug for cancer treatment side effect
Galera Therapeutics shares plunged by almost 85% after the clinical-stage biopharmaceutical company revealed its New Drug Application for its investigational therapeutic avasopasem manganese (avasopasem) for radiotherapy-induced severe oral mucositis in patients with head and neck cancer undergoing standard-of-care treatment was not approved by the Food and Drug Administration (FDA). The company said that the FDA had informed it that the data from its Phase 3 ROMAN trial and supporting data from its GT-201 trial were “not sufficiently persuasive to establish substantial evidence of avasopasem's effectiveness and safety for reducing severe oral mucositis in patients with head and neck cancer.
proactiveinvestors.com
- 1 year ago
8. Profile Summary
Galera Therapeutics, Inc. GRTX
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 2.34 M
Dividend Yield
0.00%
Description
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Contact
2 West Liberty Boulevard, Malvern, PA, 19355
https://www.galeratx.com
IPO Date
Nov. 7, 2019
Employees
7
Officers
Dr. J. Mel Sorensen M.D.
Chief Executive Officer, President & Director